Real Endpoints Marketplace announces collaboration with bluebird bio to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy
October 04, 2022 00:01 ET
|
Real Endpoints
FLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to...
Real Endpoints’ chairman, Roger Longman, named to PharmaVOICE 100
August 10, 2021 09:45 ET
|
Real Endpoints
FLORHAM PARK, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Citing his creativity, entrepreneurialism, and leadership over the last 30 years, PharmaVOICE magazine has named Roger Longman, chairman of Real...
Real Endpoints Launches the First Turn-Key Platform for Value-Based Contracting
December 09, 2020 10:45 ET
|
Real Endpoints
The RE Marketplace established with four founding health plans representing nearly 2.5 million lives. Each plan and its beneficiaries get immediate access to contracts for all biotech drugs in the...
Real Endpoints Strengthens and Broadens Access Capabilities and Reach with the Hiring of Key Executive
November 10, 2020 14:30 ET
|
Real Endpoints
FLORHAM PARK, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a leading boutique life science consultancy focused on market access, today announced it has hired Robert O’Brien as Vice...
Real Endpoints’ Susan Raiola Named to 2019 PharmaVoice 100
August 06, 2019 09:00 ET
|
Real Endpoints
MADISON, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Real Endpoints (RE), an advisory and analytics firm entirely focused on enhancing appropriate access to healthcare innovation, announced today that...
Real Endpoints Appoints Jeff Berkowitz, CEO and Director
September 13, 2018 11:14 ET
|
Real Endpoints
MADISON, N.J., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a leader in the development and implementation of proprietary tools to strengthen pharmaceutical market access for an evolving...
Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract
February 20, 2018 10:00 ET
|
Real Endpoints
SAN DIEGO, WELLESLEY, Mass. and WESTPORT, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Illumina, Inc. and Harvard Pilgrim Health Care announced on February 1 a major new value-based contract (VBC) – one...
Real Endpoints Appoints Jane F. Barlow, MD, EVP and Chief Clinical Officer
July 17, 2017 10:00 ET
|
Real Endpoints
WESTPORT, Conn., July 17, 2017 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a data, analytics, and advisory company that helps payers and biopharma companies define the value and economic impact of new...
Survey finds variability in MS treatment preferences among individual patients, and among stakeholder groups
January 31, 2017 17:16 ET
|
Real Endpoints
WESTPORT, CT--(Marketwired - January 31, 2017) - Real Endpoints, LLC (RE), a data and analytics firm focusing on assessing and quantifying pharmaceutical value, has just completed an extensive...
Move Over Gilead? AbbVie Could Bring Serious Competition to HCV Market
October 13, 2014 12:25 ET
|
Real Endpoints
WESTPORT, CT--(Marketwired - Oct 13, 2014) - Gilead's Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value assessment tool from Real...